비교리스트

 카트 문의
시장보고서
상품코드
1641756

세계의 분획혈류예비력(FFR) 시장 : 제품별, 기술별, 용도별, 최종사용자별 - 기회 분석과 산업 예측(2024-2035년)

Fractional Flow Reserve Market By Product, By Technology, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2024-2035
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 350 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전 세계 분획혈류예비력(FFR) 시장 규모는 2023년에 9억 130만 달러로 평가되며 2024-2035년 동안 연평균 9.1%의 CAGR로 성장하여 2035년에는 25억 5,834만 달러에 달할 것으로 예상됩니다. 분획혈류예비력(FFR)은 관상동맥 협착이 혈류에 미치는 영향을 평가하여 그 심각성을 평가하는 데 사용되는 진단 측정법입니다.

FFR은 관상동맥의 막힌 부분 바로 앞에서 측정된 압력(원위부 압력, Pd)과 막힌 부분의 앞쪽, 보통 대동맥이나 동맥의 건강한 부분에서 측정된 압력(근위부 압력, Pa)의 비율로 정의되며, FFR의 계산식은 Pd/Pa입니다.

Fractional Flow Reserve Market-IMG1

FFR을 평가하는 방법에는 침습적 방법과 비침습적 방법이 있습니다. 침습적 FFR은 일반적으로 관상동맥 조영술을 포함하며, 심장 카테터 검사 중에 압력 센서가 장착된 가이드와이어를 관상동맥에 삽입합니다. 이 와이어는(종종 아데노신을 사용하여) 유도 충혈 동안 협착 부위 전후의 압력을 측정합니다. 이 압력 측정값은 FFR을 계산하는 데 사용됩니다. 관상동맥 내 초음파 검사(IVUS-FFR)는 영상 진단과 압력 측정을 결합하여 동맥과 협착의 특징을 종합적으로 평가합니다. 비침습적 방법으로는 혈관조영 FFR과 컴퓨터 단층촬영(CT) 기반 FFR이 있으며, X-ray 혈관조영 FFR은 혈관을 영상화하여 혈류역학을 평가하고, CT 기반 FFR은 관상동맥의 혈류와 압력을 시뮬레이션하는 첨단 영상 기술을 사용하여 카테터 치료 없이 협착의 심각성을 파악할 수 있습니다. 없이 협착의 심각성을 알 수 있습니다.

FFR은 관상동맥 협착이 혈류에 영향을 미치는 정도를 정확하게 평가하여 의사가 협착이 허혈(심근 손상으로 이어지는 혈류 감소)을 유발할 수 있는지 여부를 판단하는 데 도움이 됩니다. 이 검사를 위해서는 아데노신을 투여하여 충혈(혈류가 최대이고 혈관 저항이 최소인 상태)을 유도해야 합니다. 건강한 동맥에서 FFR은 1과 같으며, 이는 심각한 막힘이 없음을 의미하며, FFR이 0.8 이하인 경우 심각한 막힘을 의미하며, 허혈의 예측 정확도가 높으며, FFR은 관상동맥 협착의 생리적 영향에 대한 자세한 정보를 제공하여 스텐트 또는 우회 수술의 필요 여부와 같은 치료 결정에 대한 지침이 됩니다. 의 지침이 됩니다.

심혈관질환, 특히 관상동맥질환(CAD)의 유병률 증가는 FFR 시장 성장의 주요 촉진요인입니다. 관상동맥 협착과 같은 증상이 있는 환자가 증가함에 따라 의료진은 치료 결정, 특히 혈관조영술이 필요한지 여부를 판단하기 위한 지침으로 FFR을 포함한 고급 진단 툴을 찾고 있습니다. 예를 들어, 영국 심장 재단(British Heart Foundation)의 보고서에 따르면, 2023년에는 전 세계적으로 약 1억 1,000만 명의 남성과 8,000만 명의 여성이 관상동맥 심장 질환을 앓고 있는 것으로 추정됩니다. 이 질환은 관상동맥이 좁아지거나 막혀서 심근으로 가는 혈류를 감소시키고 심하면 심장마비를 일으킬 수 있습니다.

또한, CT에서 파생된 AI 기반 FFR과 같은 기술 발전의 증가는 수술을 보다 빠르고 쉽게 접근할 수 있도록 하여 채택을 촉진하고 시장 성장을 촉진할 것입니다. 예를 들어, 덴버에 본사를 둔 의료 기술 기업 Cleerly, Inc.는 의료 영상 진단 결과를 기반으로 AI를 활용한 관상동맥 질환(CAD) 위험 평가를 제공하는 Cleerly ISCHEMIA 소프트웨어 장치를 제공하고 있습니다. 또한, 유리한 상환 정책과 최신 임상 가이드라인의 가용성은 일상적인 심혈관 치료에 FFR의 통합을 지원하여 시장 성장을 촉진하고 있습니다.

그러나 FFR 장비의 높은 가격은 특히 소규모 의료 시설과 의료 예산이 제한된 지역의 경우 여전히 큰 장벽으로 작용하여 시장 성장을 저해하고 있습니다. 또한, FFR 측정의 실시 및 해석에는 특수 장비와 훈련된 인력이 필요하기 때문에 특히 개발도상국 시장에서는 도입이 제한되어 있습니다. 반면, 비침습적 FFR 기술의 발전으로 인해 진단 절차가 보다 최소침습적이고 친숙해지면서 특히 선진국과 신흥 경제국에서 시장 성장의 기회를 제공하고 있습니다. 또한, 신흥 시장에서의 의료 인프라의 증가는 이들 지역에서 첨단 심혈관 진단 도구의 도입이 증가함에 따라 큰 성장 잠재력을 제공하고 있습니다.

분획혈류예비력 시장은 제품, 기술, 용도, 최종사용자, 지역으로 분류됩니다. 제품별로는 가이드와이어, 모니터링 시스템, 액세서리 및 소프트웨어로 분류됩니다. 기술별로 침습적 모니터링과 비침습적 모니터링으로 분류됩니다. 용도별로 시장은 멀티 브랜치 CAD와 단일 브랜치 CAD로 나뉩니다. 최종사용자별로 시장은 병원, 심장 센터, 기타로 세분화됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(일본, 중국, 인도, 호주, 한국, 기타 아시아태평양), 라틴아메리카, 중동 및 아프리카(브라질, 남아프리카, 사우디아라비아, 기타), 기타 지역으로 세분화되어 있습니다.

이해관계자를 위한 주요 이점

  • 이 보고서는 2023-2035년 분획혈류예비력(FFR) 분석의 시장 부문, 현재 동향, 추정, 역학을 정량적으로 분석하여 우세한 분획혈류예비력(FFR) 시장 기회를 파악합니다.
  • 시장 촉진요인, 시장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
  • Porter's Five Forces 분석은 이해 관계자가 이익 중심의 비즈니스 결정을 내리고 공급자와 구매자 네트워크를 강화할 수 있도록 구매자와 공급자의 잠재력을 강조합니다.
  • 분획혈류예비력(FFR) 시장 세분화에 대한 상세한 분석은 시장 기회를 결정하는 데 도움이 됩니다.
  • 각 지역의 주요 국가는 세계 시장에 대한 수익 기여도에 따라 매핑되어 있습니다.
  • 시장 기업의 포지셔닝은 벤치마킹을 용이하게 하고, 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
  • 이 보고서에는 지역별 및 세계 분획혈류예비력(FFR) 시장 동향, 주요 기업, 시장 부문, 응용 분야, 시장 성장 전략 분석이 포함되어 있습니다.

본 보고서에서 가능한 보고서 커스터마이징(추가 비용 및 일정에 대해서는 영업 담당자에게 문의)

  • 국가, 지역, 세계 수준의 환자/역학 데이터
  • 규제 가이드라인
  • 고객의 관심사에 따른 추가 기업 프로파일
  • 국가별 또는 지역별 추가 분석 : 시장 규모 및 전망
  • 기업 개요 확장 목록
  • 과거 시장 데이터
  • SWOT 분석

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
    • 영향요인
    • 주요 투자 기회
  • Porter's Five Forces 분석
  • 시장 역학
    • 성장 촉진요인
      • 심혈관질환 유병률 상승
      • 유리한 상환 정책
      • FFR에 관한 가이드라인 이용 가능성
      • 최소침습적·비침습적 수술에 대한 수요 증가
    • 성장 억제요인
      • FFR 수술과 디바이스의 고비용
    • 기회
      • 신흥 국가의 높은 성장의 가능성
      • FFR의 진보

제4장 분획혈류예비력(FFR) 시장 : 제품별

  • 개요
  • 가이드와이어
  • 모니터링 시스템
  • 액세서리·소프트웨어

제5장 분획혈류예비력(FFR) 시장 : 기술별

  • 개요
  • 침습적 모니터링
  • 비침습적 모니터링

제6장 분획혈류예비력(FFR) 시장 : 용도별

  • 개요
  • 단지 CAD
  • 다지 CAD

제7장 분획혈류예비력(FFR) 시장 : 최종사용자별

  • 개요
  • 병원
  • 심장 센터
  • 기타

제8장 분획혈류예비력(FFR) 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 기타
  • 라틴아메리카, 중동 및 아프리카
    • 브라질
    • 남아프리카공화국
    • 사우디아라비아
    • 기타

제9장 경쟁 구도

  • 소개
  • 주요 성공 전략
  • 주요 10개사 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 기업의 포지셔닝 : 2023년

제10장 기업 개요

  • Haemonetics Corporation
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Bracco
  • Koninklijke Philips N.V.
  • HeartFlow, Inc.
  • Esaote Group
  • CathWorks
  • Siemens
  • GE HealthCare
ksm 25.02.20

The global fractional flow reserve market was valued at $901.3 million in 2023, and is projected to reach $2,558.34 million by 2035, growing at a CAGR of 9.1% from 2024 to 2035.Fractional Flow Reserve (FFR) is a diagnostic measurement used to assess the severity of coronary artery stenosis (narrowing) by evaluating its impact on blood flow. FFR is defined as the ratio of the pressure measured in the coronary artery just beyond the blockage (distal pressure, Pd) to the pressure measured before the blockage, typically in the aorta or a healthy portion of the artery (proximal pressure, Pa). The formula for FFR is Pd/Pa.

Fractional Flow Reserve Market - IMG1

There are both invasive and non-invasive methods to assess FFR. Invasive FFR typically involves wired coronary angiography, where a pressure-sensor-equipped guide wire is inserted into the coronary artery during cardiac catheterization. This wire measures pressures before and after the stenosis during induced hyperemia (often using adenosine). These pressure readings are used to calculate the FFR. Intracoronary Ultrasound (IVUS-FFR), which combines imaging with pressure measurements to provide a comprehensive assessment of the artery and stenosis characteristics. Non-invasive methods include angiography-FFR and computed tomography (CT)-based FFR. X-ray Angiography-FFR uses imaging to visualize blood vessels and assess blood flow dynamics. CT-based FFR employs advanced imaging techniques to simulate blood flow and pressure in coronary arteries, providing insight into stenosis significance without catheterization.

FFR provides an accurate assessment of how much narrowing of coronary arteries is affecting blood flow, helping physicians determine whether the stenosis is likely to cause ischemia (reduced blood flow leading to heart muscle damage). The procedure requires the induction of hyperemia, a state of maximum blood flow and minimal vascular resistance, achieved by administering adenosine. In a healthy artery, FFR equals 1, indicating no significant obstruction. An FFR value of 0.8 or lower suggests a severe blockage, with high accuracy in predicting ischemia. FFR helps guide treatment decisions, including whether a stent or bypass surgery is needed by providing detailed information about the physiological impact of a coronary stenosis.

Increase in prevalence of cardiovascular diseases, particularly coronary artery diseases (CAD), is a major driver of FFR market growth. As more patients suffer from conditions such as coronary stenosis, healthcare providers seek advanced diagnostic tools including FFR to guide treatment decisions, specifically to determine whether angiography is necessary. For instance, as per the report of British Heart Foundation, in 2023, it was estimated that globally around 110 million men and 80 million women have coronary heart disease. These conditions result in the narrowing or blocking of coronary arteries, leading to reduced blood flow to the heart muscle and, in severe cases, heart attacks, which lead to surge in demand for fractional flow reserve procedure.

In addition, rise in technological advancements, such as AI-based FFR derived from CT, make the procedure faster and more accessible, encouraging its adoption, thereby fostering market growth. For instance, Cleerly, Inc., a Denver-based healthcare technology company provides Cleerly ISCHEMIA software device that delivers AI-powered coronary artery disease (CAD) risk assessments based on medical imaging results. Further, favorable reimbursement policies and the availability of updated clinical guidelines support FFR integration into routine cardiovascular care, boosting market growth.

However, high cost of FFR devices remains a significant barrier, particularly for smaller healthcare facilities or regions with limited healthcare budgets, thereby restricting market growth. In addition, the need for specialized equipment and trained personnel to perform and interpret FFR measurements limit adoption, especially in underdeveloped markets. On the other hand, advancements in non-invasive FFR technologies, which make diagnostic procedures less invasive and more accessible, provide an opportunity for market growth especially in the developed and emerging economies. In addition, the rise in healthcare infrastructure in emerging markets offers significant growth potential as these regions increasingly adopt advanced cardiovascular diagnostic tools.

The fractional flow reserve market is segmented into product, technology, application, end user, and region. On the basis of the product, it is classified into guidewires, monitoring systems, and accessories & software. On the basis of technology, the market is categorized into invasive monitoring and non-invasive monitoring. On the basis of application, the market is bifurcated into multi-vessel CAD and single-vessel CAD. On the basis of end user, the market is fragmented into hospitals, cardiac centres, and others. Region-wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA).

The major companies profiled in the report include Haemonetics Corporation, Abbott Laboratories, Boston Scientific Corporation, Bracco, Koninklijke Philips N.V., HeartFlow, Inc., CathWorks, Siemens, GE HealthCare, and Esaote Group. The key players operating in the market have adopted product approval, acquisition, and agreement as their key strategies to expand their product portfolio. For instance, in December 2023, Haemonetics Corporation completed its previously announced acquisition of OpSens Inc., a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology. OpSens offers the OptoWire, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (FFR).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the fractional flow reserve market analysis from 2023 to 2035 to identify the prevailing fractional flow reserve market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the fractional flow reserve market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global fractional flow reserve market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Application

  • Single vessel CAD
  • Multi vessel CAD

By Product

  • Guidewires
  • Monitoring Systems
  • Accessories and Software

By Technology

  • Invasive Monitoring
  • Non invasive Monitoring

By End User

  • Hospitals
  • Cardiac Centres
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Abbott Laboratories
    • Boston Scientific Corporation
    • Bracco
    • CathWorks
    • Esaote Group
    • GE HealthCare
    • Haemonetics Corporation
    • HeartFlow, Inc.
    • Koninklijke Philips N.V.
    • Siemens

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rising prevalence of cardiovascular diseases
      • 3.4.1.2. Favorable reimbursement policies
      • 3.4.1.3. Availability of guidelines for FFR
      • 3.4.1.4. Growing demand for minimally invasive & non-invasive procedures
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of FFR procedures and devices
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in emerging countries
      • 3.4.3.2. Advancements in FFR

CHAPTER 4: FRACTIONAL FLOW RESERVE MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Guidewires
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Monitoring Systems
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Accessories and Software
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: FRACTIONAL FLOW RESERVE MARKET, BY TECHNOLOGY

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Invasive Monitoring
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Non invasive Monitoring
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: FRACTIONAL FLOW RESERVE MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Single vessel CAD
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Multi vessel CAD
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: FRACTIONAL FLOW RESERVE MARKET, BY END USER

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Hospitals
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Cardiac Centres
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country
  • 7.4. Others
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by region
    • 7.4.3. Market share analysis by country

CHAPTER 8: FRACTIONAL FLOW RESERVE MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key market trends, growth factors and opportunities
    • 8.2.2. Market size and forecast, by Product
    • 8.2.3. Market size and forecast, by Technology
    • 8.2.4. Market size and forecast, by Application
    • 8.2.5. Market size and forecast, by End User
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Market size and forecast, by Product
      • 8.2.6.1.2. Market size and forecast, by Technology
      • 8.2.6.1.3. Market size and forecast, by Application
      • 8.2.6.1.4. Market size and forecast, by End User
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Market size and forecast, by Product
      • 8.2.6.2.2. Market size and forecast, by Technology
      • 8.2.6.2.3. Market size and forecast, by Application
      • 8.2.6.2.4. Market size and forecast, by End User
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Market size and forecast, by Product
      • 8.2.6.3.2. Market size and forecast, by Technology
      • 8.2.6.3.3. Market size and forecast, by Application
      • 8.2.6.3.4. Market size and forecast, by End User
  • 8.3. Europe
    • 8.3.1. Key market trends, growth factors and opportunities
    • 8.3.2. Market size and forecast, by Product
    • 8.3.3. Market size and forecast, by Technology
    • 8.3.4. Market size and forecast, by Application
    • 8.3.5. Market size and forecast, by End User
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Market size and forecast, by Product
      • 8.3.6.1.2. Market size and forecast, by Technology
      • 8.3.6.1.3. Market size and forecast, by Application
      • 8.3.6.1.4. Market size and forecast, by End User
      • 8.3.6.2. France
      • 8.3.6.2.1. Market size and forecast, by Product
      • 8.3.6.2.2. Market size and forecast, by Technology
      • 8.3.6.2.3. Market size and forecast, by Application
      • 8.3.6.2.4. Market size and forecast, by End User
      • 8.3.6.3. UK
      • 8.3.6.3.1. Market size and forecast, by Product
      • 8.3.6.3.2. Market size and forecast, by Technology
      • 8.3.6.3.3. Market size and forecast, by Application
      • 8.3.6.3.4. Market size and forecast, by End User
      • 8.3.6.4. Italy
      • 8.3.6.4.1. Market size and forecast, by Product
      • 8.3.6.4.2. Market size and forecast, by Technology
      • 8.3.6.4.3. Market size and forecast, by Application
      • 8.3.6.4.4. Market size and forecast, by End User
      • 8.3.6.5. Spain
      • 8.3.6.5.1. Market size and forecast, by Product
      • 8.3.6.5.2. Market size and forecast, by Technology
      • 8.3.6.5.3. Market size and forecast, by Application
      • 8.3.6.5.4. Market size and forecast, by End User
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Market size and forecast, by Product
      • 8.3.6.6.2. Market size and forecast, by Technology
      • 8.3.6.6.3. Market size and forecast, by Application
      • 8.3.6.6.4. Market size and forecast, by End User
  • 8.4. Asia-Pacific
    • 8.4.1. Key market trends, growth factors and opportunities
    • 8.4.2. Market size and forecast, by Product
    • 8.4.3. Market size and forecast, by Technology
    • 8.4.4. Market size and forecast, by Application
    • 8.4.5. Market size and forecast, by End User
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. Japan
      • 8.4.6.1.1. Market size and forecast, by Product
      • 8.4.6.1.2. Market size and forecast, by Technology
      • 8.4.6.1.3. Market size and forecast, by Application
      • 8.4.6.1.4. Market size and forecast, by End User
      • 8.4.6.2. China
      • 8.4.6.2.1. Market size and forecast, by Product
      • 8.4.6.2.2. Market size and forecast, by Technology
      • 8.4.6.2.3. Market size and forecast, by Application
      • 8.4.6.2.4. Market size and forecast, by End User
      • 8.4.6.3. India
      • 8.4.6.3.1. Market size and forecast, by Product
      • 8.4.6.3.2. Market size and forecast, by Technology
      • 8.4.6.3.3. Market size and forecast, by Application
      • 8.4.6.3.4. Market size and forecast, by End User
      • 8.4.6.4. Australia
      • 8.4.6.4.1. Market size and forecast, by Product
      • 8.4.6.4.2. Market size and forecast, by Technology
      • 8.4.6.4.3. Market size and forecast, by Application
      • 8.4.6.4.4. Market size and forecast, by End User
      • 8.4.6.5. South Korea
      • 8.4.6.5.1. Market size and forecast, by Product
      • 8.4.6.5.2. Market size and forecast, by Technology
      • 8.4.6.5.3. Market size and forecast, by Application
      • 8.4.6.5.4. Market size and forecast, by End User
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Market size and forecast, by Product
      • 8.4.6.6.2. Market size and forecast, by Technology
      • 8.4.6.6.3. Market size and forecast, by Application
      • 8.4.6.6.4. Market size and forecast, by End User
  • 8.5. LAMEA
    • 8.5.1. Key market trends, growth factors and opportunities
    • 8.5.2. Market size and forecast, by Product
    • 8.5.3. Market size and forecast, by Technology
    • 8.5.4. Market size and forecast, by Application
    • 8.5.5. Market size and forecast, by End User
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Market size and forecast, by Product
      • 8.5.6.1.2. Market size and forecast, by Technology
      • 8.5.6.1.3. Market size and forecast, by Application
      • 8.5.6.1.4. Market size and forecast, by End User
      • 8.5.6.2. South Africa
      • 8.5.6.2.1. Market size and forecast, by Product
      • 8.5.6.2.2. Market size and forecast, by Technology
      • 8.5.6.2.3. Market size and forecast, by Application
      • 8.5.6.2.4. Market size and forecast, by End User
      • 8.5.6.3. Saudi Arabia
      • 8.5.6.3.1. Market size and forecast, by Product
      • 8.5.6.3.2. Market size and forecast, by Technology
      • 8.5.6.3.3. Market size and forecast, by Application
      • 8.5.6.3.4. Market size and forecast, by End User
      • 8.5.6.4. Rest of LAMEA
      • 8.5.6.4.1. Market size and forecast, by Product
      • 8.5.6.4.2. Market size and forecast, by Technology
      • 8.5.6.4.3. Market size and forecast, by Application
      • 8.5.6.4.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product mapping of top 10 player
  • 9.4. Competitive dashboard
  • 9.5. Competitive heatmap
  • 9.6. Top player positioning, 2023

CHAPTER 10: COMPANY PROFILES

  • 10.1. Haemonetics Corporation
    • 10.1.1. Company overview
    • 10.1.2. Key executives
    • 10.1.3. Company snapshot
    • 10.1.4. Operating business segments
    • 10.1.5. Product portfolio
    • 10.1.6. Business performance
    • 10.1.7. Key strategic moves and developments
  • 10.2. Abbott Laboratories
    • 10.2.1. Company overview
    • 10.2.2. Key executives
    • 10.2.3. Company snapshot
    • 10.2.4. Operating business segments
    • 10.2.5. Product portfolio
    • 10.2.6. Business performance
    • 10.2.7. Key strategic moves and developments
  • 10.3. Boston Scientific Corporation
    • 10.3.1. Company overview
    • 10.3.2. Key executives
    • 10.3.3. Company snapshot
    • 10.3.4. Operating business segments
    • 10.3.5. Product portfolio
    • 10.3.6. Business performance
  • 10.4. Bracco
    • 10.4.1. Company overview
    • 10.4.2. Key executives
    • 10.4.3. Company snapshot
    • 10.4.4. Operating business segments
    • 10.4.5. Product portfolio
  • 10.5. Koninklijke Philips N.V.
    • 10.5.1. Company overview
    • 10.5.2. Key executives
    • 10.5.3. Company snapshot
    • 10.5.4. Operating business segments
    • 10.5.5. Product portfolio
    • 10.5.6. Business performance
  • 10.6. HeartFlow, Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key executives
    • 10.6.3. Company snapshot
    • 10.6.4. Operating business segments
    • 10.6.5. Product portfolio
  • 10.7. Esaote Group
    • 10.7.1. Company overview
    • 10.7.2. Key executives
    • 10.7.3. Company snapshot
    • 10.7.4. Operating business segments
    • 10.7.5. Product portfolio
  • 10.8. CathWorks
    • 10.8.1. Company overview
    • 10.8.2. Key executives
    • 10.8.3. Company snapshot
    • 10.8.4. Operating business segments
    • 10.8.5. Product portfolio
    • 10.8.6. Key strategic moves and developments
  • 10.9. Siemens
    • 10.9.1. Company overview
    • 10.9.2. Key executives
    • 10.9.3. Company snapshot
    • 10.9.4. Operating business segments
    • 10.9.5. Product portfolio
    • 10.9.6. Business performance
    • 10.9.7. Key strategic moves and developments
  • 10.10. GE HealthCare
    • 10.10.1. Company overview
    • 10.10.2. Key executives
    • 10.10.3. Company snapshot
    • 10.10.4. Operating business segments
    • 10.10.5. Product portfolio
    • 10.10.6. Business performance
    • 10.10.7. Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제